185 related articles for article (PubMed ID: 23766517)
1. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
3. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
4. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of Nrf2 and ERK pathway in papillary thyroid carcinoma].
Chen YM; Wei L; Lin X; Zhang WJ; Wu JF; Xue G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(12):941-945. PubMed ID: 29798417
[No Abstract] [Full Text] [Related]
6. NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer.
Zhang TT; Qu N; Sun GH; Zhang L; Wang YJ; Mu XM; Wei WJ; Wang YL; Wang Y; Ji QH; Zhu YX; Shi RL
Int J Oncol; 2018 Aug; 53(2):685-693. PubMed ID: 29901070
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 as a novel diagnostic biomarker for papillary thyroid carcinoma.
Wang Z; Li J; Liu Z; Yue L
Eur J Histochem; 2023 Mar; 67(2):. PubMed ID: 36951264
[TBL] [Abstract][Full Text] [Related]
9. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
[TBL] [Abstract][Full Text] [Related]
10. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
[TBL] [Abstract][Full Text] [Related]
11. A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways.
Gan FF; Ling H; Ang X; Reddy SA; Lee SS; Yang H; Tan SH; Hayes JD; Chui WK; Chew EH
Toxicol Appl Pharmacol; 2013 Nov; 272(3):852-62. PubMed ID: 23899529
[TBL] [Abstract][Full Text] [Related]
12. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
13. Papillary Thyroid Carcinoma: A Malignant Tumor with Increased Antioxidant Defense Capacity.
Rovcanin BR; Gopcevic KR; Kekic DLj; Zivaljevic VR; Diklic ADj; Paunovic IR
Tohoku J Exp Med; 2016 Oct; 240(2):101-11. PubMed ID: 27615359
[TBL] [Abstract][Full Text] [Related]
14. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
15. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin.
Tanigawa S; Fujii M; Hou DX
Free Radic Biol Med; 2007 Jun; 42(11):1690-703. PubMed ID: 17462537
[TBL] [Abstract][Full Text] [Related]
16. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
[TBL] [Abstract][Full Text] [Related]
17. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
18. Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells.
Yang X; Wang D; Ma Y; Xu X; Zhu Z; Wang X; Deng H; Li C; Chen M; Tong J; Yamanaka K; An Y
Toxicol Appl Pharmacol; 2015 Dec; 289(2):231-9. PubMed ID: 26420645
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and Nrf2 signaling in McArdle disease.
Kitaoka Y; Ogborn DI; Nilsson MI; Mocellin NJ; MacNeil LG; Tarnopolsky MA
Mol Genet Metab; 2013 Nov; 110(3):297-302. PubMed ID: 23906480
[TBL] [Abstract][Full Text] [Related]
20. Nrf2-Keap1 antioxidant defense and cell survival signaling are upregulated by 17β-estradiol in homocysteine-treated dopaminergic SH-SY5Y cells.
Chen CS; Tseng YT; Hsu YY; Lo YC
Neuroendocrinology; 2013; 97(3):232-41. PubMed ID: 22948038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
